{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:04:58Z","timestamp":1762542298778},"reference-count":35,"publisher":"Japanese Society of Veterinary Science","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Vet. Med. Sci.","The Journal of Veterinary Medical Science"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1292\/jvms.13-0590","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T13:41:54Z","timestamp":1402926114000},"page":"1383-1387","source":"Crossref","is-referenced-by-count":2,"title":["Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Control          in Healthy Beagle Dogs with Normal Gluco-Homeostasis"],"prefix":"10.1292","volume":"76","author":[{"given":"Hitomi","family":"ODA","sequence":"first","affiliation":[{"name":"School of Veterinary Nursing and Technology, Faculty of              Veterinary Science, Nippon Veterinary and Life Science University, 1\u20137\u20131 Kyonancho,              Musashino, Tokyo 180\u20138602, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"MORI","sequence":"additional","affiliation":[{"name":"School of Veterinary Nursing and Technology, Faculty of              Veterinary Science, Nippon Veterinary and Life Science University, 1\u20137\u20131 Kyonancho,              Musashino, Tokyo 180\u20138602, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"LEE","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, Faculty of Veterinary              Science, Nippon Veterinary and Life Science University, 1\u20137\u20131 Kyonancho, Musashino,              Tokyo 180\u20138602, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"SAEKI","sequence":"additional","affiliation":[{"name":"School of Veterinary Nursing and Technology, Faculty of              Veterinary Science, Nippon Veterinary and Life Science University, 1\u20137\u20131 Kyonancho,              Musashino, Tokyo 180\u20138602, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"ARAI","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, Faculty of Veterinary              Science, Nippon Veterinary and Life Science University, 1\u20137\u20131 Kyonancho, Musashino,              Tokyo 180\u20138602, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinori","family":"SAKO","sequence":"additional","affiliation":[{"name":"School of Veterinary Nursing and Technology, Faculty of              Veterinary Science, Nippon Veterinary and Life Science University, 1\u20137\u20131 Kyonancho,              Musashino, Tokyo 180\u20138602, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"122","reference":[{"key":"1","unstructured":"1. Aaboe, K., Knop, F. K., Vilsb\u00f8ll, T., Deacon, C. F., Holst, J. J., Madsbad, S. and Krarup, T. 2010. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. <i>Diabetes Obes. Metab.<\/i> 12: 323\u2013333."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Baggio, L. L. and Drucker, D. J. 2007. Biology of incretins: GLP-1 and GIP. <i>Gastroenterology<\/i> 132: 2131\u20132157.","DOI":"10.1053\/j.gastro.2007.03.054"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Beconi, M. G., Reed, J. R., Teffera, Y., Xia, Y. Q., Kochansky, C. J., Liu, D. Q., Xu, S., Elmore, C. S., Ciccotto, S., Hora, D. F., Stearns, R. A. and Vincent, S. H. 2007. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. <i>Drug Metab. Dispos.<\/i> 35: 525\u2013532.","DOI":"10.1124\/dmd.106.013110"},{"key":"4","unstructured":"4. Bergman, A. J., Stevens, C., Zhou, Y., Yi, B., Laethem, M., De Smet, M., Snyder, K., Hilliard, D., Tanaka, W., Zeng, W., Tanen, M., Wang, A. Q., Chen, L., Winchell, G., Davies, M. J., Ramael, S., Wagner, J. A. and Herman, G. A. 2006. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. <i>Clin. Ther.<\/i> 28: 55\u201372."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bode, B. W., Testa, M. A., Magwire, M., Hale, P. M., Hammer, M., Blonde, L., Garber, A., LEAD-3 Study Group2010. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. <i>Diabetes Obes. Metab.<\/i> 12: 604\u2013612.","DOI":"10.1111\/j.1463-1326.2010.01196.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Catchpole, B., Ristic, J. M., Fleeman, L. M. and Davison, L. J. 2005. Canine diabetes mellitus: can old dogs teach us new tricks? <i>Diabetologia<\/i> 48: 1948\u20131956.","DOI":"10.1007\/s00125-005-1921-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chia, C. W., Carlson, O. D., Kim, W., Shin, Y. K., Charles, C. P., Kim, H. S., Melvin, D. L. and Egan, J. M. 2009. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. <i>Diabetes<\/i> 58: 1342\u20131349.","DOI":"10.2337\/db08-0958"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B. and Holst, J. J. 1995. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. <i>Diabetes<\/i> 44: 1126\u20131131.","DOI":"10.2337\/diabetes.44.9.1126"},{"key":"9","unstructured":"9. Debraekeloer, J., Gross, K. and Zicker, S. 2000. Chapter 9. Normal dogs. pp.213\u2013260. <i>In:<\/i> Small Animal Clinical Nutrition, 4th ed. (Hand, M. M., Thatcher, C. D., Remillard, R. L., Roudebush, P. and Novotny, B. J. eds.), Mark Morris Institute, Topeka."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Drucker, D. J. 2007. The role of gut hormones in glucose homeostasis. <i>J. Clin. Invest.<\/i> 117: 24\u201332.","DOI":"10.1172\/JCI30076"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Drucker, D. J. and Nauck, M. A. 2006. The incretin system: glucagon-like peptide- 1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. <i>Lancet<\/i> 368: 1696\u20131705.","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"12","unstructured":"12. Ellis, S. L., Moser, E. G., Snell-Bergeon, J. K., Rodionova, A. S., Hazenfield, R. M. and Garg, S. K. 2011. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. <i>Diabet. Med.<\/i> 28: 1176\u20131181."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fakhoury, W. K., Lereun, C. and Wright, D. 2010. A meta-analysis of placebo- controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. <i>Pharmacology<\/i> 86: 44\u201357.","DOI":"10.1159\/000314690"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Garber, A. J. 2012. Novel GLP-1 receptor agonists for diabetes. <i>Expert Opin. Investig. Drugs<\/i> 21: 45\u201357.","DOI":"10.1517\/13543784.2012.638282"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Garg, S. K., Moser, E. G., Bode, B. W., Klaff, L. J., Hiatt, W. R., Beatson, C. and Snell-Bergeon, J. K. 2013. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. <i>Endocr. Pract.<\/i> 19: 19\u201328.","DOI":"10.4158\/EP12100.OR"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Giampietro, O., Giampietro, C., Bartola, L. D., Masoni, M. C. and Matteucci, E. 2013. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. <i>Drug Des. Devel. Ther.<\/i> 7: 99\u2013104.","DOI":"10.2147\/DDDT.S38346"},{"key":"17","unstructured":"17. Hari Kumar, K. V., Shaikh, A. and Prusty, P. 2013. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. <i>Diabetes Res. Clin. Pract.<\/i> 100: e55\u2013e58."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Harrison, L. B., Mora, P. F., Clark, G. O. and Lingvay, I. 2013. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. <i>J. Investig. Med.<\/i> 61: 40\u201344.","DOI":"10.2310\/JIM.0b013e318279b7d6"},{"key":"19","unstructured":"19. Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., Lasseter, K. C., Kipnes, M. S., Snyder, K., Hilliard, D., Tanen, M., Cilissen, C., de Smet, M., de Lepeleire, I., Van, VanDyck, K., Wang, A. Q., Zeng, W., Davies, M. J., Tanaka, W., Holst, J. J., Deacon, C. F., Gottesdiener, K. M. and Wagner, J. A. 2006. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. <i>J. Clin. Endocrinol. Metab.<\/i> 91: 4612\u20134619."},{"key":"20","unstructured":"20. Herman, G. A., Stevens, C., Van Dyck, K., Bergman, A., Yi, B., De Smet, M., Snyder, K., Hilliard, D., Tanen, M., Tanaka, W., Wang, A. Q., Zeng, W., Musson, D., Winchell, G., Davies, M. J., Ramael, S., Gottesdiener, K. M. and Wagner, J. A. 2005. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. <i>Clin. Pharmacol. Ther.<\/i> 78: 675\u2013688."},{"key":"21","unstructured":"21. Hillaire-Buys, D., Bertrand, G., Chapal, J., Puech, R., Ribes, G. and Loubati\u00e8res-Mariani, M. M. 1993. Stimulation of insulin secretion and improvement of glucose tolerance in rat and dog by the P2y-purinoceptor agonist, adenosine-5\u2032-O-(2-thiodiphosphate). <i>Br. J. Pharmacol.<\/i> 109: 183\u2013187."},{"key":"22","unstructured":"22. Ionut, V., Liberty, I. F., Hucking, K., Lottati, M., Stefanovski, D., Zheng, D. and Bergman, R. N. 2006. Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. <i>Am. J. Physiol. Endocrinol. Metab.<\/i> 291: E779\u2013E785."},{"key":"23","unstructured":"23. Iwamoto, Y., Tajima, N., Kadowaki, T., Nonaka, K., Taniguchi, T., Nishii, M., Arjona Ferreira, J. C. and Amatruda, J. M. 2010. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. <i>Diabetes Obes. Metab.<\/i> 12: 613\u2013622."},{"key":"24","unstructured":"24. Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., Marsilio, F., McCann, M. E., Patel, R. A., Petrov, A., Scapin, G., Patel, S. B., Roy, R. S., Wu, J. K., Wyvratt, M. J., Zhang, B. B., Zhu, L., Thornberry, N. A. and Weber, A. E. 2005. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active ipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. <i>J. Med. Chem.<\/i> 48: 141\u2013151."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kutoh, E. 2011. Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. <i>J. Med. Case Rep.<\/i> 5: 117.","DOI":"10.1186\/1752-1947-5-117"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lee, W. C., Dekoven, M., Bouchard, J., Massoudi, M. and Langer, J. 2014. Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. <i>Diabetes Obes. Metab. <\/i>5: 117.","DOI":"10.1111\/dom.12285"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Luo, J., Nguyen, K., Chen, M., Tran, T., Hao, J., Tian, B., Rulifson, I. C., Zhang, Y., Tian, L., Zhang, Y., Lopez, E., Lin, D. C., Wang, Y., Ma, Z., Houze, J. and Guo, Z. 2013. Evaluating insulin secretagogues in a humanized mouse model with functional human islets. <i>Metabolism<\/i> 62: 90\u201399.","DOI":"10.1016\/j.metabol.2012.07.010"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. McIntyre, N., Holdsworth, C. D. and Turner, D. S. 1965. Intestinal factors in the control of insulin secretion. <i>J. Clin. Endocrinol. Metab.<\/i> 25: 1317\u20131324.","DOI":"10.1210\/jcem-25-10-1317"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Mest, H. J. and Mentlein, R. 2005. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. <i>Diabetologia<\/i> 48: 616\u2013620.","DOI":"10.1007\/s00125-005-1707-5"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Nauck, M. A., Homberger, E., Siegel, E. G., Allen, R. C., Eaton, R. P., Ebert, R. and Creutzfeldt, W. 1986. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. <i>J. Clin. Endocrinol. Metab.<\/i> 63: 492\u2013498.","DOI":"10.1210\/jcem-63-2-492"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Nonaka, K., Kakikawa, T., Sato, A., Okuyama, K., Fujimoto, G., Kato, N., Suzuki, H., Hirayama, Y., Ahmed, T., Davies, M. J. and Stein, P. P. 2008. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. <i>Diabetes Res. Clin. Pract.<\/i> 79: 291\u2013298.","DOI":"10.1016\/j.diabres.2007.08.021"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Oda, H., Mori, A., Lee, P., Saeki, K., Ishioka, K., Arai, T. and Sako, T. 2013. Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs. <i>Res. Vet. Sci.<\/i> 95: 381\u2013388.","DOI":"10.1016\/j.rvsc.2013.04.003"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Pridal, L., Ingwersen, S. H., Larsen, F. S., Holst, J. J., Adelhorst, K. and Kirk, O. 1995. Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7\u201336) amide in plasma. <i>J. Pharm. Biomed. Anal.<\/i> 13: 841\u2013850.","DOI":"10.1016\/0731-7085(95)01312-9"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Vilsb\u00f8ll, T. and Garber, A. J. 2012. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. <i>Diabetes Obes. Metab.<\/i> 14: 41\u201349.","DOI":"10.1111\/j.1463-1326.2012.01579.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Vilsb\u00f8ll, T., Agers\u00f8, H., Krarup, T. and Holst, J. J. 2003. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. <i>J. Clin. Endocrinol. Metab.<\/i> 88: 220\u2013224.","DOI":"10.1210\/jc.2002-021053"}],"container-title":["Journal of Veterinary Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/76\/10\/76_13-0590\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T01:14:27Z","timestamp":1617066867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/76\/10\/76_13-0590\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1292\/jvms.13-0590","relation":{},"ISSN":["0916-7250","1347-7439"],"issn-type":[{"value":"0916-7250","type":"print"},{"value":"1347-7439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}